🍪 CompoundTalk uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsPharmacology & MechanismsGIP receptor pharmacology — what worked for you? Page 2

GIP receptor pharmacology — what worked for you?

Dr.AddMedPHL Sat, Nov 23, 2024 at 8:17 PM 19 replies 1,906 viewsPage 2 of 4
InsuranceTom
Senior Member
1,345
7,890
Mar 2024
Connecticut
Nov 25, 2024 at 7:20 AM#6
RetaRick_CA said:
SURMOUNT-1 landed around 20.9% mean weight loss at 15mg over 72 weeks, against roughly 15% for semaglutide 2.4mg in STEP 1.

I read this differently from RetaRick_CA, on substance rather than tone. The "tirzepatide is simply better" summary irritates me. It is better on mean weight loss, and the cardiovascular outcome evidence is far thinner than semaglutide's. If the reason for treating is cardiovascular risk rather than weight, the evidence base points the other way.

9 4lisa_labSD, adam_van, Dr.SurgeonPGH and 6 others
Reply Quote Save Share Report
jason_paloalto
Member
212
890
Nov 2024
Palo Alto, CA
Nov 25, 2024 at 10:18 PM#7

One concrete data point for the thread. Numbers worth memorising for this class: Tmax one to three days for the weekly peptides, terminal half-life about a week for semaglutide and about five days for tirzepatide, steady state at four to five half-lives, subcutaneous bioavailability high enough that site choice is irrelevant.

Last edited: Nov 26, 2024 at 3:18 AM
8 3Dr.PathRoch, mona_PHX, andrew_nyc and 5 others
Reply Quote Save Share Report
LibrarianMeg
Senior Member
1,678
7,890
Mar 2024
Baltimore, MD
Nov 26, 2024 at 1:16 PM#8
InsuranceTom said:
The "tirzepatide is simply better" summary irritates me.

There is a second half to this that has not been said yet. The mechanism is more central than most summaries suggest. Receptor agonism in the arcuate nucleus activates POMC neurons and inhibits AgRP/NPY signalling, and the downstream MC4R pathway is the same one disrupted in monogenic obesity — convergent genetic evidence that the target is the right one. Peripherally there is glucose-dependent insulin secretion, glucagon suppression and delayed gastric emptying, but the gastric component largely adapts over months while the central effect persists, which is why the durable effect is appetite rather than fullness.

Worth separating that from the pharmacology, which this thread keeps folding into the same question. They behave differently and the advice does not transfer.

Last edited: Nov 26, 2024 at 3:16 PM
7 2julia.endo, JessicaM_2024, TomFromTexas and 4 others
Reply Quote Save Share Report

Janoshik Analytical — Independent Testing

Trusted third-party HPLC & mass spectrometry analysis. Verify peptide purity with the lab the community relies on. Independent. Accurate. Transparent.

Verify Your Peptides

GL Biochem (Shanghai) Ltd. — Direct Manufacturer

Est. 1998. The synthesis house behind the vials you send for testing. ISO 9001 and cGMP certified, 1,500+ staff, batch-specific COA with every order.

Browse GL Biochem
jim_asheville
Member
289
1,234
Aug 2024
Asheville, NC
Nov 27, 2024 at 4:14 AM#9

One thing that is still open after Dr.SurgeonPGH’s answer:

How much of the tirzepatide advantage is the GIP component and how much is simply that the dose ladder goes higher in receptor-occupancy terms?

Last edited: Nov 27, 2024 at 7:14 AM
6 1wanda_boise, NurseAsh_DET, BenResearch_OR and 3 others
Reply Quote Save Share Report
Dr.AddMedPHL
Senior Member
1,234
6,234
Mar 2024
Philadelphia, PA
Nov 30, 2024 at 4:02 AM#10

Reporting back.

I stayed at 10mg. Another six months, another 7kg, no new side effects, and my reading of the dose-response says the last two steps were never going to be worth what they cost me.

38 11JessicaM_2024, TomFromTexas, mike.trainer_LA and 35 others
Reply Quote Save Share Report

Similar Threads

GLP-1R desensitization — β-arrestin-mediated internalization18 replies
Biased agonism at GLP-1R — Gs vs β-arrestin signaling balance13 replies
Semaglutide albumin binding and the C-18 fatty acid linker17 replies
GIP receptor pharmacology — why GIP agonism enhances GLP-113 replies
Glucagon receptor signaling — hepatic glycogenolysis and lipolysis16 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register